This is, to my eyes, one of the most exiting abstracts from @myESMO #ESMO25 #Presidential #PRAME, expressed in many tumours 😉 #AdoptiveCellTherapy achieves a 🔝ORR (67%)🥳 Proof of concept ✅ Expand concept to other tumours? New target of interest? #ESMOAmbassadors

#ESMO25 AGITG DYNAMIC-III: ctDNA-guided adj ChT de-escalation in stage III CC 📊 968 pts | 72.5% ctDNA– | 3y RFS 85.3% vs 88.1% (NI not met) 💊 Oxa 34.8% vs 88.6% | Gr≥3 AEs 6.2% vs 10.6% 🎯 De-escalation feasible, reduced toxicity with similar outcomes in low-risk (T1–3N1)

RT @DrChoueiri: Powerhouse masterful discussion by @GIcancerDoc! Cuts through noise, pressures the stats, and maps where this actually fits…

Year 2 of #ESMOGI #oncology journal editorial board hard at work @esmo #ESMO25 @ben_irit @KarynAGoodman @RachelRiechelm2 Drs. Florian Lordick, Thierry Andre, Anelisa Cotinhu and so many others! We would love to consider your #cancerresearch for publication. #cancer

Irish connections #ESMO25 presidential dinner from Medical school @UCC to UAE, Beaumont & St James’s hospital to @pmcancercentre & @TheChristieNHS @LizzySmyth1 @graokane

KRAS G12D inhibitors work in #PDAC! More confirmatory data of this presented at #ESMO25 @myESMO I am so so happy to see these waterfall plots 😊 👉GFH375-VS7375 mono 👉HRS4642 with GemNabPaclitaxel Great discussion by #MaeveLowery KRAS - easy to test! 🥳🥳 #ESMOAmbassadors

# ESMO25 Clinical Practice Guidelines 1 @LizzySmyth1 @ArndtVogel : access the full guidelines https://t.co/Srrj4buTA6

Lost in lung cancer 🫁 updates? Lymphoma guidelines just changed again? Don’t worry — everyone’s lost in Messe Berlin 🧭 We’ll help you find your way through the data. Join us at the #ESMO25 NSCLC and Lymphoma Guidelines Session 🕐2.45pm 📍7.1c Bonn Auditorium @myESMO

Great ESMO Guidelines session with @ArndtVogel & @LizzySmyth1 on #HCC. We discussed intermediate-stage challenges, 1L vs 2L decisions, and how national approvals & reimbursement shape real-world practice — still many questions to answer! #ESMO #LiverCancer #MyESMO 🇩🇪

Next up: learn the latest in #melanoma and #HCC with the fabulous @TeresaSAmaral and @ArndtVogel #ESMO25 Guidelines Session 1 When: ⏰ 10.15am (that means you need to start walking now!) Where :📍7.1 Ground Floor Bonn 7.1c See you soon! @myESMO #ESMOAmbassadors

📢 Calling all oncology AI users (that'll be all of us then...) Use this tech the right way! @myESMO gives the first guidance framework for AI in the clinic #ELCAP Very proud to work with an awesome team led by Jakob Kather on this innovative project. Launched at #ESMO25 💪

Practice-shaping presidential caliber from @Prof_Nadia_H! DESTINY-Breast11: neoadjuvant T-DXd→THP tops ddAC-THP on pCR 67.3% vs 56.3% (Δ11.2%, p=0.003). Early positive trend in EFS. #ESMO25 #BreastCancer @myESMO @Annals_Oncology @DanaFarber

The @myESMO Presidential I, happening in 30 min at Berlin auditorium! Practice-changing data presented ! @curijoey @stolaney1 #ESMO25

#ESMO25 ?TDxD challenger? Bispecific HER2 anbenitamab shows promise in trastuzumab resistant #gastriccancer. ✅No ILD... Small study. 🇨🇳 only. Need larger international trials but this is encouraging... #ESMOAmbassadors

We have seen the mountain ⛰️ top! MATTERHORN OS #ESMO25 OS continues to ⬆️over time (~7% 3y) Benefit independent of PD-L1 Enough now to adopt as SOC? #ESMOAmbassadors

And we're off!! #ESMO25 opening ceremony 🎇🎆🎇 📍 Berlin Auditorium now! #ESMOAmbassadors

Adding the finishing touches 👩‍💻 to my presentation for tomorrow at #ESMO25 ... Team Upper GI - I promise not to talk about PD-L1 (again!) 16:00 🕐 Munich Auditorium. See you there! #ESMOAmbassadors #CancerResearch

Here we go again.. #ESMO25 ✈️🚄🚝 Get to Berlin early 🕐 for the UGI orals Friday 17/10 afternoon.. I'm watching out for the Matterhorn ⛰️ update...will we see an OS benefit 👀? See you this day next week! #ESMOAmbassadors

#ESMO25: Discover the latest #CancerResearch insights brought to you by #ESMOAmbassadors and join the conversation in #oncology. 🔗 https://t.co/YZZN0sQyBS

Cancer care is more than biomarkers... Grateful 🙏 for the opportunity expand my oncology horizons 🌅 writing this essay with Laura Nimmon and Gary Rodin.. Broadening our view of power in clinician–patient relationships in oncology - The Lancet Oncology